IP Library › Granted Patent US 12,714,713
Granted Patent B2
US 12,714,713 · App. 18/034,749 · Granted Aug 25, 2026

Method of treating cancers with alkyne substituted quinazoline derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,714,713
App. No.
18/034,749
Filed
May 1, 2023
Granted
Aug 25, 2026
Kind
B2
Art Unit
1626
USPC
514/231.5
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2025
From: EPSTEIN, DAVID M.
To: BLACK DIAMOND THERAPEUTICS, INC.
Reel/Frame 070772/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2023
From: BUCK, ELIZABETH; O'CONNOR, MATTHEW; ROMASHKO, DARLENE; LIN, TAI-AN; WRONA, IWONA; LUCAS, MATTHEW C; ROBERTS, CHRIS; SMITH, SHERRI; WATERS, NIGEL
To: BLACK DIAMOND THERAPEUTICS, INC.
Reel/Frame 065907/0257 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2023
From: RIDGELINE THERAPEUTICS GMBH
To: BLACK DIAMOND THERAPEUTICS, INC.
Reel/Frame 065907/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2023
From: FLOHR, ALEXANDER; ARISTA, LUCA; OTTAVIANI, GIORGIO
To: RIDGELINE THERAPEUTICS GMBH
Reel/Frame 065907/0286 →
Continuity (6)
Provisional Application 63244540 · Sep 15, 2021
Provisional Application 63237782 · Aug 27, 2021
Provisional Application 63218717 · Jul 6, 2021
Provisional Application 63190067 · May 18, 2021
Provisional Application 63166045 · Mar 25, 2021
Related Publication 20240075042A1 · Mar 7, 2024
References Cited (159)
US 6127374A · Bridges · 2000 [cited by applicant]
US 6867201B2 · Kath et al. · 2005 [cited by applicant]
US 7294629B2 · Kitano et al. · 2007 [cited by applicant]
US 8735409B2 · Zhang et al. · 2014 [cited by applicant]
US 8987284B2 · Shen et al. · 2015 [cited by applicant]
US 9090588B2 · Shen et al. · 2015 [cited by applicant]
US 9187459B2 · Shen et al. · 2015 [cited by applicant]
US 9890187B2 · Odysseos et al. · 2018 [cited by applicant]
US 10221191B2 · Hadari et al. · 2019 [cited by applicant]
US 10309966B2 · Sibilia · 2019 [cited by applicant]
US 10640524B2 · Odysseos et al. · 2020 [cited by applicant]
US 10870657B2 · Hadari et al. · 2020 [cited by applicant]
US 11034672B1 · Flohr et al. · 2021 [cited by applicant]
US 12435046B2 · Lucas et al. · 2025 [cited by applicant]
US 20080200433A1 · Suzuki et al. · 2008 [cited by applicant]
US 20100087482A1 · Haber et al. · 2010 [cited by applicant]
US 20130035350A1 · Zhang et al. · 2013 [cited by applicant]
US 20150126537A1 · Zhang · 2015 [cited by applicant]
US 20160039838A1 · Zhang et al. · 2016 [cited by applicant]
US 20190382382A1 · Shen et al. · 2019 [cited by applicant]
US 20200299315A1 · Shen et al. · 2020 [cited by applicant]
US 20220041613A1 · Flohr et al. · 2022 [cited by applicant]
US 20220273665A1 · McGovern et al. · 2022 [cited by applicant]
US 20220298120A1 · Lucas et al. · 2022 [cited by examiner]
US 20220340523A1 · Dakin et al. · 2022 [cited by applicant]
US 20220363666A1 · Flohr et al. · 2022 [cited by applicant]
CN 1492860A · 2004 [cited by applicant]
CN 101010304A · 2007 [cited by applicant]
CN 101679384A · 2010 [cited by applicant]
CN 102382065A · 2012 [cited by applicant]
CN 102452989A · 2012 [cited by applicant]
CN 102516232A · 2012 [cited by applicant]
CN 102731485A · 2012 [cited by applicant]
CN 103797006A · 2014 [cited by applicant]
CN 103965120A · 2014 [cited by applicant]
CN 103998040A · 2014 [cited by applicant]
CN 104119350A · 2014 [cited by applicant]
CN 105348271A · 2016 [cited by applicant]
CN 108473464A · 2018 [cited by applicant]
CN 109265449A · 2019 [cited by applicant]
CN 113382986A · 2021 [cited by applicant]
EP 1000039A1 · 2000 [cited by applicant]
EP 1249451A2 · 2002 [cited by applicant]
EP 1369418A1 · 2003 [cited by applicant]
EP 1000039B1 · 2004 [cited by applicant]
EP 1506962A2 · 2005 [cited by applicant]
EP 1792898A1 · 2007 [cited by applicant]
EP 2612860A1 · 2013 [cited by applicant]
JP 5155391B2 · 2013 [cited by applicant]
WO WO9630347A1 · 1996 [cited by applicant]
WO WO9738983A1 · 1997 [cited by applicant]
WO WO9906378A1 · 1999 [cited by applicant]
WO WO9909016A1 · 1999 [cited by applicant]
WO WO0044728A1 · 2000 [cited by applicant]
WO WO0047212A1 · 2000 [cited by applicant]
WO WO0078735A1 · 2000 [cited by applicant]
WO WO0177104A1 · 2001 [cited by applicant]
WO WO0218370A1 · 2002 [cited by applicant]
WO WO0250043A1 · 2002 [cited by applicant]
WO WO02066445A1 · 2002 [cited by applicant]
WO WO03045939A1 · 2003 [cited by applicant]
WO WO03089439A1 · 2003 [cited by applicant]
WO WO2004069791A2 · 2004 [cited by applicant]
WO WO2005026157A1 · 2005 [cited by applicant]
WO WO2005107758A1 · 2005 [cited by applicant]
WO WO2006025490A1 · 2006 [cited by applicant]
WO WO2007013950A2 · 2007 [cited by applicant]
WO WO2007055513A1 · 2007 [cited by applicant]
WO WO2007055514A1 · 2007 [cited by applicant]
WO WO2008020711A1 · 2008 [cited by applicant]
WO WO2008033749A2 · 2008 [cited by applicant]
WO WO2008150118A2 · 2008 [cited by applicant]
WO WO2008157500A1 · 2008 [cited by applicant]
WO WO2010036629A2 · 2010 [cited by applicant]
WO WO2012122058A2 · 2012 [cited by applicant]
WO WO2012136099A1 · 2012 [cited by applicant]
WO WO2013008217A1 · 2013 [cited by applicant]
WO WO2013013640A1 · 2013 [cited by applicant]
WO WO2013131424A1 · 2013 [cited by applicant]
WO WO2013173254A1 · 2013 [cited by applicant]
WO WO2014007951A2 · 2014 [cited by applicant]
WO WO2014071824A1 · 2014 [cited by applicant]
WO WO2014177038A1 · 2014 [cited by applicant]
WO WO2015043515A1 · 2015 [cited by applicant]
WO WO2015054572A1 · 2015 [cited by applicant]
WO WO2016023217A1 · 2016 [cited by applicant]
WO WO2016055982A1 · 2016 [cited by applicant]
WO WO2016105582A1 · 2016 [cited by applicant]
WO WO2016203406A1 · 2016 [cited by applicant]
WO WO2017055859A1 · 2017 [cited by applicant]
WO WO2020068867A1 · 2020 [cited by applicant]
WO WO2020068873A1 · 2020 [cited by applicant]
WO WO2021030711A1 · 2021 [cited by applicant]
WO WO2021154997A1 · 2021 [cited by applicant]
WO WO2021195206A1 · 2021 [cited by applicant]
WO WO2021213800A1 · 2021 [cited by applicant]
WO WO2022040377A1 · 2022 [cited by applicant]
WO WO2022076671A1 · 2022 [cited by applicant]
WO WO2022094464A1 · 2022 [cited by applicant]
WO WO2023049168A1 · 2023 [cited by applicant]
Moffitt Cancer Center ( www. moffitt.org/cancers/brain-tumor/leptomeningeal-disease/, 2025) (Year: 2025). [cited by examiner]
Thomas and Ramirez (Ochsner Journal 2017; 17: 362-378) (Year: 2017). [cited by examiner]
Cominelli et al. (JNCI J Natl Cancer Inst (2015); 107(5): djv041) (Year: 2015). [cited by examiner]
Limam et al. (Ann Biol Clin 2019; 77(3): 307-317) (Year: 2019). [cited by examiner]
Sattler, M. et al., “A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine,” J Clin Med. Mar. 1, 2023;12(5):1936, 13 pages, doi: 10.3390/jcm12051936. [cited by applicant]
Wang, D.D. et al., “Personalized prediction of EGFR mutation-induced drug resistance in lung cancer,” Scientific Reports, 2013;3:2855, DOI: 10.1038/srep02855, 8 pages. [cited by applicant]
Argiris, A et al., “Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial,” Journal of Clinica… [cited by applicant]
Asadollahi-Baboli, M., “In silica evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors,” Mol Divers, 20:729-739 (2016). [cited by applicant]
Blair et al., “Structure-guided development of affinity probes for tyrosine kinases using chemical genetics,” Nature Chemical Biology, Apr. 2007, 3:229-238. [cited by applicant]
Caira, M. R., “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry (Jan. 1, 1998); 198:163-208. [cited by applicant]
Carmi, C. et al. “Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides,” J. Med. Chem., Jan. 26, 2012, 55:2251-2264 (including Supporting Information, 25 pages total). [cited by applicant]
CAS Registry No. 1012054-59-9, dated Apr. 4, 2008, 1 page. [cited by applicant]
CAS Registry No. 1092364-38-9, dated Dec. 31, 2008, 1 page. [cited by applicant]
CAS Registry No. 1110813-31-4, dated Feb. 23, 2009, 1 page. [cited by applicant]
CAS Registry No. 1131863-89-2, dated Apr. 3, 2009, 1 page. [cited by applicant]
CAS Registry No. 1197953-54-0, dated Dec. 17, 2009, 1 page. [cited by applicant]
CAS Registry No. 1213269-23-8, dated Mar. 23, 2010, 1 page. [cited by applicant]
CAS Registry No. 1214265-56-1, dated Mar. 24, 2010, 1 page. [cited by applicant]
CAS Registry No. 1214265-57-2, dated Mar. 24, 2010, 1 page. [cited by applicant]
CAS Registry No. 1374640-70-6, dated May 29, 2012, 1 page. [cited by applicant]
CAS Registry No. 1398833-56-1, dated Oct. 3, 2012, 1 page. [cited by applicant]
CAS Registry No. 1421373-65-0, dated Feb. 19, 2013, 1 page. [cited by applicant]
CAS Registry No. 183319-69-9, dated Nov. 22, 1996, 1 page. [cited by applicant]
CAS Registry No. 184475-35-2, dated Dec. 26, 1996, 1 page. [cited by applicant]
CAS Registry No. 187724-61-4, dated Mar. 28, 1997, 1 page. [cited by applicant]
CAS Registry No. 194423-15-9, dated Sep. 24, 1997, 1 page. [cited by applicant]
CAS Registry No. 196612-93-8, dated Oct. 31, 1997, 1 page. [cited by applicant]
CAS Registry No. 212141-54-3, dated Oct. 4, 1998, 1 page. [cited by applicant]
CAS Registry No. 231277-92-2, dated Aug. 7, 1999, 1 page. [cited by applicant]
CAS Registry No. 257933-82-7, dated Mar. 3, 2000, 1 page. [cited by applicant]
CAS Registry No. 267243-28-7, dated May 30, 2000, 1 page. [cited by applicant]
CAS Registry No. 439081-18-2, dated Jul. 17, 2002, 1 page. [cited by applicant]
CAS Registry No. 443913-73-3, dated Aug. 14, 2002, 1 page. [cited by applicant]
CAS Registry No. 451493-31-5, dated Sep. 16, 2002, 1 page. [cited by applicant]
CAS Registry No. 497839-62-0, dated Mar. 11, 2003, 1 page. [cited by applicant]
CAS Registry No. 610798-31-7, dated Oct. 30, 2003, 1 page. [cited by applicant]
CAS Registry No. 692737-80-7, dated Jun. 14, 2004, 1 page. [cited by applicant]
CAS Registry No. 698387-09-6, dated Jun. 24, 2004, 1 page. [cited by applicant]
CAS Registry No. 714971-09-2, dated Jul. 23, 2004, 1 page. [cited by applicant]
CAS Registry No. 781613-23-8, dated Nov. 16, 2004, 1 page. [cited by applicant]
CAS Registry No. 848133-17-5, dated Apr. 8, 2005, 1 page. [cited by applicant]
CAS Registry No. 848942-61-0, dated Apr. 21, 2005, 1 page. [cited by applicant]
CAS Registry No. 871026-44-7, dated Jan. 3, 2006, 1 page. [cited by applicant]
CAS Registry No. 897383-62-9, dated Jul. 28, 2006, 1 page. [cited by applicant]
CAS Registry No. 934660-93-2, dated May 13, 2007, 1 page. [cited by applicant]
Dermer, G.B., “Another Anniversary for the War on Cancer,” Bio/Technology, 12:320, 1 page (Mar. 1994). [cited by applicant]
Freshney R.I., et al., “Culture of Animal Cells,” A Manual of Basic Technique, 1983, Alan R. Liss, Inc., New York, p. 4 and pp. 129-133 (9 total pages). [cited by applicant]
Golub, T. R., et al., “Molecular classification of cancer: class discovery and class prediction by gene expression monitoring”, Science (1999); 286: 531-537. [cited by applicant]
Martins, R. G. et al., “Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial,” Journal of Clinical Oncology, 31(11):1415-1421… [cited by applicant]
Peereboom, D. M. et al., “Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme,” J Neurooncol, 98:93-99 (2010). [cited by applicant]
Petrylak, D. P. et al., “Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium,” Southwest Oncology Group, 105:317-321 (2009); doi… [cited by applicant]
Philips, G. K. et al., “A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102,” Annals of Oncology, 20:1074-1079 (… [cited by applicant]
Reardon, D.A. et al., “Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma,” Neuro-Oncology, Advance Access p… [cited by applicant]
Shen, W. et al. “A41 EO1001: A First-in-Class Irreversible Pan-ErbB Inhibitor with Excellent Brain Penetration,” Journal of Thoracic Oncology, 15(2 Suppl):S26, Abstract A41 (Feb. 2020). [cited by applicant]
Shen, W. et al. “NT113, a potent and selective pan-ErbB inhibitor, is efficacious in vivo and has high brain penetrance,” [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Re… [cited by applicant]
Simone, J. V. (1996) “Introduction” in Cecil Textbook of Medicine. 20th Ed., vol. I . J. Claude Bennet and F. Plum (Eds.) W.B. Sauders Co.; pp. 1004-1010. [cited by applicant]
Van Den Bent, M. J. et al., “Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034,” J Clin Oncol, 27:1268-1274 (2009). [cited by applicant]
Yin, D. et al. “Studying the Conformation of a Receptor Tyrosine Kinase in Solution by Inhibitor-Based Spin Labeling,” Angew Chem Int Ed Engl., 56(29):8417-8421, with Supporting Information, 24 pages (Jul. 10, 2017). do… [cited by applicant]
Yoshida, Y. et al. “NT113, a pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification,” Mol. Cancer Ther., Dec. 2014, 13(12):2919-29. [cited by applicant]